Key facts
- This page summarizes Myriam Curet's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Sep 2023, 20:09.
Myriam Curet - 18 Sep 2023 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- Director
- Issuer ticker
- NKTR
- Reported as of
- 18 Sep 2023
- Net transaction value
- -$3,008
- SEC form
- 4
- Accepted by SEC
- 20 Sep 2023, 20:09:30 UTC
- Prior SEC filing
- 11 Aug 2023
- Next SEC filing
- 17 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- Mark A. Wilson, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Myriam Curet filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 20 Sep 2023.
Change
- Previous filing in this sequence was filed on 11 Aug 2023.
- Current net transaction value: -$3,008.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NKTR
transaction
Common Stock
Sale
- Transaction value
- $3,008
- Shares
- -4,359
- Change %
- -14%
- Price
- $0.6900
- Shares after
- 27,418
- Date
- 18 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NKTR
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +85,000
- Change %
- Price
- $0.000000
- Shares after
- 85,000
- Date
- 19 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,000
- Exercise price
- $0.6800
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the number of shares required to be sold by the reporting person to cover tax obligations in connection with the vesting of certain RSUs held by the reporting person. This sale is mandated by the reporting person's previous election under the Issuer's equity incentive plans to require the satisfaction of tax obligations to be funded by a "sell to cover" transaction.
Footnote F2
This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023.